Key result
There was no significant difference in the genotype and allele frequencies of Factor V Leiden, Factor II, MTHFR, and Factor V H1299R polymorphisms between women with recurrent pregnancy loss and controls (p>0.05).
Why the study?
Are Factor V Leiden G1691A, Factor II G20210A, MTHFR C677T, and Factor V H1299R polymorphisms associated with recurrent pregnancy loss?
Case-Control (n=255)
Are Factor V Leiden G1691A, Factor II G20210A, MTHFR C677T, and Factor V H1299R polymorphisms associated with recurrent pregnancy loss?
The study found no significant association between common thrombophilia-related genetic polymorphisms and recurrent pregnancy loss.
Answers are grounded in this paper and cite their sources.
No association seen in this cohort; leaves open the role of these polymorphisms in RPL pending larger studies.
The distribution of factor V Leiden G1691A, factor II G20210A, MTHFR C677T, and factor V H1299R polymorphisms known to predispose to thrombophilia in 215 cases and 40 controls admitted with indication of recurrent pregnancy loss (RPL) was investigated. Genotyping was performed by melting curve analysis using simultaneous PCR (RT-PCR). There was no difference between genotype and allele frequencies in the case and control groups in terms of the polymorphisms examined (p>0.05). In the genotype distribution of the Factor V gene G1691A polymorphism, 12.6% GA in the case group and 90.0% GG (wild) genotypes in the control group were found to be higher than the other genotypes. In the genotype distribution of the factor II gene G20210A polymorphism, the GG (wild) genotype was found to be higher in 94.5% and 97.5%, respectively, in the case group and control group than the other genotypes. In the genotype distribution of MTHFR gene C677T polymorphism, 43.7% CC (wild) in the case group and 40.0% CT genotype in the control group were found to be higher than the other genotypes. In the genotype distribution of the factor V gene A4070G polymorphism, 87.4% AA (wild) in the case group and 80% AA (wild) genotype in the control group were found to be higher than the other genotypes. However, the frequency of risk allele A for factor V Leiden G1691A (6.8% and 5%), the frequency of risk allele A for factor II gene G20210A (3% and 1.2%), MTHFR gene C677T were determined in the case and control groups. The frequency of the T allele (35.9% and 42.5%), which is the risk allele for A4070G, and the frequency of the G allele (6.5% and 16.6%), which is the risk allele for the factor V gene A4070G, were determined. When our study results were evaluated, no relationship was found between RPL and factor V Leiden G1691A, factor II G20210A, MTHFR C677T, and factor V A4070G polymorphisms.
No takes yet. Share an insight, caveat, or question.
Erdoğan et al. (2022) conducted a case-control in Recurrent pregnancy loss (n=255). Thrombophilia gene polymorphisms (Factor V Leiden, Factor II, MTHFR, Factor V H1299R) vs. Control group without recurrent pregnancy loss was evaluated on Difference in genotype and allele frequencies of thrombophilia polymorphisms (p=>0.05). There was no significant difference in the genotype and allele frequencies of Factor V Leiden, Factor II, MTHFR, and Factor V H1299R polymorphisms between women with recurrent pregnancy loss and controls (p>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: